by Nicola Blackburn | Nov 16, 2022
In recognition of Pancreatic Cancer Awareness Month, this November iconic buildings over Australia will light up purple to raise awareness for the disease and to celebrate and honour survivors and loved ones. Pancreatic cancer is the third leading cause of cancer...
by Nicola Blackburn | Sep 9, 2022
A new clinical trial for people with advanced pancreatic cancer, has now commenced in Australia. The trial led by Amplia Therapeutics, in collaboration with Professor Paul Timpson from the Invasion and Metastasis Lab at The Garvan Institute of Medical Research, will...
by Gloria Jeong | Jul 6, 2022
Pancreatic cancer is one of the most aggressive cancers and five-year survival rates are just 10%. A very small number of patients live longer, with less than 2% surviving more than 10 years after diagnosis. Researchers have been working to understand how this cancer...
by Gloria Jeong | Jun 16, 2022
The Avner Australian Pancreatic Cancer Matrix Atlas group (APMA) will investigate a potential new way to improve immunotherapy outcomes for patients with pancreatic cancer using a class of drug that can reduce the metabolic rewiring of the cancer cells thanks to a...
by Gloria Jeong | Nov 17, 2021
November is recognised as World Pancreatic Cancer Awareness Month. We take time to raise awareness of the disease, celebrate survivors and acknowledge pancreatic cancer research. Pancreatic cancer has now become the third leading cause of cancer deaths...
by Nicola Blackburn | Nov 1, 2021
A new approach to ‘prime’ the tumour environment may improve how effective chemotherapy is for pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer. In preclinical models, a team from the Invasion and Metastasis Lab at The Garvan...
